Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.
- 47% decline in operating revenue to $11.5 million
- Draft Medicare Local Coverage Determination proposes coverage for Cxbladder tests
- Total laboratory throughput down 16.3%, commercial tests down 23.8%
- Raised $36.1 million in equity post-year-end
- Expansion in Asia Pacific with new clinical pathways
Medicare Draft Coverage Signals Turning Point
Pacific Edge Limited (NZX:PEB) endured a challenging FY26, reporting a $35.8 million net loss after tax on the back of a 47.4% plunge in operating revenue to $11.5 million. The steep decline was primarily driven by the loss of Medicare coverage for its Cxbladder bladder cancer diagnostic tests in the US from April 2025, which had previously accounted for over half of its operating revenue.
However, the company’s fortunes may be poised for a turnaround following a key milestone achieved after the balance date: the publication of a draft Local Coverage Determination (LCD) by Novitas, the Medicare Administrative Contractor. This draft policy proposes Medicare coverage for Pacific Edge’s Cxbladder Triage and Triage Plus tests, with the latter priced at a substantial premium of US$1,328 per test, 75% higher than the legacy Triage test’s US$760 price. The finalisation of this LCD, anticipated by the end of 2026, could unlock a path to accelerated growth and improved profitability.
Operational Impact and Capital Management Amid Headwinds
The Medicare non-coverage led to a 16.3% drop in total laboratory throughput to 24,190 tests, with commercial tests falling 23.8% to 18,783. Despite these setbacks, Pacific Edge saw steady growth in the Asia Pacific region, supported by new clinical pathway adoptions at institutions such as Singapore General Hospital and Townsville University Hospital.
Pacific Edge responded with prudent capital management, reducing its monthly cash burn by 27.7% in the second half of FY26 to $2.4 million. To bolster its balance sheet and fund ongoing operations, the company raised $36.1 million in new equity through a $25.4 million placement and a $10.7 million retail offer, both approved post-year-end.
Clinical Evidence and Commercial Momentum Build
The company’s strategy centres on three pillars: adoption and revenue generation, evidence and coverage, and research and innovation. The draft LCD not only proposes coverage but explicitly excludes competing biomarkers due to insufficient evidence, deepening Pacific Edge’s competitive moat.
Commercial payer momentum also gained traction, with several US insurers including Blue Cross Blue Shield plans and Highmark adopting positive medical policies for Cxbladder tests, collectively covering millions of lives. These endorsements complement the inclusion of Cxbladder Triage in the American Urological Association (AUA) Microhematuria Guideline with a ‘Grade A’ evidence rating, further validating the clinical utility of Pacific Edge’s tests.
Research and Innovation Drive Future Growth
Pacific Edge continues to advance its product pipeline, notably developing Cxbladder Surveillance Plus, expected to receive provisional pricing of US$1,800 per test and claim-by-claim reimbursement by mid-2027. The company is also progressing a kit-based in vitro diagnostic (IVD) version of Triage Plus, which would enable decentralized testing through authorized partner laboratories globally, improving turnaround times and local reimbursement opportunities.
While kit-based IVD development is currently paused, Pacific Edge maintains a working prototype and ongoing validation efforts, positioning itself for broader international market access.
Sustainability and Governance Remain Core Focuses
Beyond commercial and clinical progress, Pacific Edge underscores its commitment to sustainability, reporting on social impact, environmental stewardship, and governance practices. The company highlights initiatives to reduce its carbon intensity per test, noting a 40% reduction in greenhouse gas emissions compared to traditional cystoscopy diagnostic pathways. It also reports strong employee engagement and diversity efforts, alongside rigorous risk management frameworks and compliance with multiple international quality standards.
Board and Leadership Evolution
Governance saw a notable change with Simon Flood appointed Chairman in December 2025, bringing extensive global investment and healthcare industry experience. The Board maintains a balance of independent directors and diverse skills, overseeing the company’s strategic direction amid a complex regulatory and commercial environment.
Pacific Edge’s CEO Dr Peter Meintjes emphasises the validation of their evidence-driven strategy and the company’s readiness to leverage the Medicare draft coverage to restore growth and profitability. The company’s financial statements, audited by PwC New Zealand, reflect the material uncertainties related to Medicare coverage finalisation and funding, but the recent capital raise and draft LCD provide a foundation for cautious optimism.
Bottom Line?
Pacific Edge’s FY26 losses highlight the cost of Medicare coverage loss, but the draft LCD and fresh capital create a pivotal opportunity to regain footing and scale.
Questions in the middle?
- How swiftly will Novitas finalise the draft LCD and what impact will delays have on Pacific Edge’s recovery?
- Can commercial payers accelerate adoption in the US to offset Medicare coverage gaps in the near term?
- Will the kit-based IVD development resume soon enough to support international expansion beyond laboratory services?